Facebooktwittergoogle_plusredditlinkedinmail
Back to November 2016 Newsletter

OmniPod Artificial Pancreas System Clinical Trial

By Lisa Foster-McNulty, MSN, RN, CDE

If you are interested in participating in a study involving the use of the OmniPod Horizon Hybrid Closed Loop System, you might want to check out ClinicalTrials.gov to see if you qualify.

This fall, Insulet, the maker of the OmniPod system, announced that the first patient completed the feasibility study of the Omnipod Horizon Automated Glucose Control System.  The use of a personal Model Predictive Control algorithm with the Omnipod platform will be evaluated in the full study using 20 adults who have Type 1 diabetes.  This will occur in a clinical research center setting so data can be collected and utilized to fine-tune the algorithm in later studies, leading up to submission to the FDA.

Insulet acquired the UC Santa Barbara Artificial Pancreas algorithm.  Jordan Pinsker, MD is a senior research physician at William Sansum Diabetes Center.  Along with colleagues, he played a major role in the development of this algorithm.  He and his colleagues will be participating in Insulet’s artificial pancreas clinical trials.  They will contribute to the clinical and development pathway as Insulet works toward bringing this technology to a commercially available product. 

The Omnipod Horizon System would be one integrated system comprised of an on-body Omnipod pump, a Dexcom Continuous Glucose Monitor (CGM), a modified version of Insulet’s hand-held controller, and an advanced security system.  The algorithm looks toward future blood glucose (BG) levels, adjusting insulin delivery to optimize BG outcomes for the user.  It is expected to improve both clinical outcomes and quality of life for users.